Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 6/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12444456 | 0.87 | MAPT (0.47) | MAPK1TP53HSP90AA1HSP90AB1LMNA | |
| SCHEMBL2146871 | 0.83 | MAPT (0.38) | LMNAHPGD | |
| SCHEMBL1503297 | 0.79 | MAPT (0.43) | MAPK1PDE5ATP53LMNAHPGD | |
| SCHEMBL1503147 | 0.78 | ALDH1A1 (0.39) | MAPK1PPARG | |
| SCHEMBL24065242 | 0.78 | HDAC1 (0.47) | MAPK1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL2147119 | 0.77 | ALDH1A1 (0.36) | MAPK1LMNA | |
| SCHEMBL13577658 | 0.75 | MAOB (0.38) | MAPK1 | |
| SCHEMBL1503145 | 0.74 | MAOB (0.37) | MAPK1 | |
| SCHEMBL12444469 | 0.73 | POLB (0.40) | POLBHDAC3HDAC6ROCK2CNR2 | |
| SCHEMBL12444452 | 0.72 | HDAC3 (0.36) | HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | MONTREAL HEART INSTITUTE (CA) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | MAPK1 2839/4885POLB 4581/4885PDE5A 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.